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ABSTRACT: A critical bottleneck for the use of metal−organic frameworks
(MOFs) as drug delivery systems has been allowing them to reach their
intracellular targets without being degraded in the acidic environment of the
lysosomes. Cells take up particles by endocytosis through multiple biochemical
pathways, and the fate of these particles depends on these routes of entry. Here,
we show the eﬀect of functional group incorporation into a series of Zr-based
MOFs on their endocytosis mechanisms, allowing us to design an eﬃcient drug
delivery system. In particular, naphthalene-2,6-dicarboxylic acid and 4,4′-
biphenyldicarboxylic acid ligands promote entry through the caveolin-pathway,
allowing the particles to avoid lysosomal degradation and be delivered into the
cytosol and enhancing their therapeutic activity when loaded with drugs.
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■ INTRODUCTION
Nanotechnology has attracted increasing interest over the past
decades, especially in the ﬁeld of medicine, where eﬀorts have
been directed toward the development of nanoparticulate drug
delivery systems (DDSs) able to deliver drugs to speciﬁc cells.
Nanoparticulate delivery vectors can overcome issues related to
the use of free drugs such as their high toxicity, high and
frequent doses, healthy tissue damage, nonspeciﬁc delivery, and
short circulating half-lives.1 Indeed, DDSs can maximize the
bioavailability of the drug, both at speciﬁc places in the body
and over time, by providing a slow release, speciﬁc targeting
and delivery, and corresponding reduced toxicity, while
maintaining the therapeutic eﬀect of the cargo drug.2,3 To
date, several types of nanoparticles have been evaluated for
drug delivery.4 Among them, metal−organic frameworks
(MOFs) have arisen as favorable candidates for this challenging
application.5−8 Their large pore volumes and surface areas,
combined with their tunable surface chemistry and pore size,
make them particularly interesting for drug delivery by allowing
the selection and design of biocompatible and biodegradable
systems. Several antiviral, anticancer, and antibacterial agents, as
well as nucleic acids and biological gases, have been successfully
entrapped in diﬀerent MOFs.9−15 In addition to the use of
pristine MOFs, we recently proposed the use of amorphous
MOFs for drug delivery.16,17 By collapsing the MOFs’ porosity
around previously adsorbed drug molecules, release of the
cargo can be extended from 2 to more than 30 days in the
∼200 nm systems that are able to cross the cellular membrane.
Optimal MOFs for drug delivery need to be versatile to load
and deliver diﬀerent compounds. However, one of the main
limitations for translating MOFs to real drug delivery
applications is the limited number of studies18−20 detailing
the penetration of MOF particles into cells. Indeed, an eﬃcient
MOF needs to be able to penetrate into cells and, more
importantly, release its cargo molecules in the correct
intracellular location. Although small molecules can enter
cells by simple passive diﬀusion, nanoparticles generally require
an energy-dependent process known as endocytosis, a
mechanism present in all eukaryotic cells.21,22 Importantly,
the fate of the nanoparticles and hence their therapeutic eﬀect
after entering the cell is dependent on the endocytic pathways
they enter through. However, no general guidelines for MOF
particle internalization have been established to date due to the
complexity of these mechanisms. All in all, endocytosis is an
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extremely cell dependent process, where several characteristics
of the particles play a signiﬁcant role in cellular uptake, such as
size, shape, surface charge, and chemistry.23,24
The size of particles, and thus the size of the membrane
invagination, gives a ﬁrst natural way of classifying the diﬀerent
pathways that cells use to internalize particles. We can deﬁne
macroscale endocytosis as phagocytosis and macropinocytosis.
The former process relates to the ingestion of large particles
(>0.5 μm) by speciﬁc types of cells such as neutrophils,
monocytes, and macrophages.25−27 Macropinocytosis is a
nonspeciﬁc process that refers to the uptake of large amounts
of extracellular ﬂuid along with any particles present in it.21 On
the other hand, microscale endocytosis processes can be
divided into three subgroups depending on the existence of
protein coatings on the formed vesicles: (i) clathrin; (ii)
caveolae; and (iii) clathrin- and caveolae-independent endocy-
tosis.27,28 Clathrin-mediated endocytosis is a speciﬁc pathway
where receptors are responsible for cargo recognition, followed
by the formation of clathrin-coated vesicles, which are usually
up to 200 nm in size.29 These vesicles merge with early
endosomes, mature into late endosomes, and then fuse with
lysosomes, leading to the hydrolysis of the DDS and its cargo,
consequently nullifying its therapeutic eﬀect.30 Caveolae-
mediated endocytosis on the other hand is associated with
the formation of lipid raft-enriched ﬂask-shaped invaginations
coated with caveolin.22,31 Particles internalized via caveolae-
mediated endocytosis can be delivered later to diﬀerent
locations inside the cell. For instance, the formed vesicles can
fuse with early endosomes and then with lysosomes for further
degradation, as in the case of clathrin-mediated endocytosis.
More interestingly, the particles internalized through this route
can also be delivered to a pH neutral compartment called the
caveosome and then transported to a ﬁnal intracellular location,
thus avoiding lysosomal degradation of the DDS and
cargo.32−34 Finally, other clathrin- and caveolae-independent
endocytosis pathways are present in many cells; however, these
are both less signiﬁcant and less well understood than the
previous cases.22,35 To design new MOF-based DDSs capable
of bypassing lysosomal degradation, it is critical to understand
the factors determining which endocytosis pathway they go
through.
We have previously reported the development of a complete
methodology to study the pathways through which MOFs enter
cells.18 We demonstrated that particles of the Zr-based MOF
UiO-66 (UiO, University of Oslo), 260 nm in size, were able to
partially escape from endosomes and avoid acidic degradation
in the lysosomes, whereas 150 nm particles were destroyed in
these compartments. Indeed, lysosomes need to be circum-
vented to avoid cargo degradation due to the low pH and the
presence of enzymes. Since the intracellular traﬃcking is
aﬀected not only by particle size but by the way DDSs interact
with the membranes, we have tuned the surface chemistry of a
family of Zr-based MOFs by including a series of functional
groups on the organic ligands. We did not control/tune the
particle size of these MOFs to avoid the presence of modulators
that could aﬀect the surface chemistry, but included a range of
UiO-66 MOFs with diﬀerent particle size for comparison. We
report the eﬀect of linker functionalization (and subsequent
changes to the outer surfaces) of the MOFs on endocytosis
pathways and eﬃciency, and use this information to prepare an
optimal DDS with enhanced endocytosis eﬃcacy and improved
ability to avoid lysosomal entrapment.
■ RESULTS AND DISCUSSION
Zirconium-based MOFs are a promising option for drug
delivery applications due to their low toxicity,36 with UiO-66
showing an IC50 value of 1.50 ± 0.15 mg/mL after 24 h of
exposure.16 The structure of this well-studied MOF contains
Zr-oxo clusters connected by bridging BDC linkers to give an
overall composition [Zr6O4(OH)4(BDC)6]n (where BDC =
1,4-benzene dicarboxylate), with large porosity (SBET = 1200 m
2
g−1, Vp = 0.5 cm
3 g−1) and two cavities (with diameters of ca. 8
and 11 Å).16,37−39 To ﬁnd a MOF with optimal endocytic
characteristics, we ﬁrst prepared a series of UiO-66 samples
with diﬀerent particles sizes: 50, 75, 92, 260, and 652 nm; we
named these structures xZr-L1, where x is the particle size (see
Table 1). Second, we prepared a range of UiO-66-like materials
with diﬀerent surface chemistries by substituting the original
BDC linker with functionalized linkers as well as extended
linkers.40,41 Scheme 1 shows the six diﬀerent linkers (L1−L6)
utilized to build the Zr-based MOFs (herein termed Zr-L1 to
Zr-L6). L1 is BDC, used for UiO-66; L2−L4 are BDC
functionalized with -Br, -NO2, and -NH2, respectively; and L5
and L6 (naphthalene-2,6-dicarboxylic acid and 4,4′-biphenyldi-
carboxylic acid, respectively) are extended linkers.
We loaded the ﬂuorescent molecule calcein into all the
MOFs to allow their intracellular detection using ﬂow
cytometry and confocal microscopy. We selected calcein
Table 1. Colloidal Analysis of Nonloaded Zr-L1 Samples of Diﬀerent Particles Sizes (i.e., xZr-L1) Alongside Functionalized (Zr-
L2, Zr-L3, and Zr-L4) and Extended (Zr-L5 and Zr-L6) Derivatives as Well as Their Calcein Uptakes
eﬀective diameter (nm)b polydispersity index z-potential (mV)
MOF particle size (nm)a PBS growth media PBS growth media water growth media calcein loading (wt %)
50Zr-L1 50 ± 2 517 ± 40 238 ± 11 0.507 0.429 0.5 −9.5 2.7
75Zr-L1 75 ± 3 575 ± 16 480 ± 21 0.581 0.479 12.3 −10.2 2.2
92Zr-L1 92 ± 2 210 ± 2 161 ± 1 0.411 0.207 14.2 −11.2 2.2
260Zr-L1 260 ± 21 328 ± 13 272 ± 12 0.295 0.167 18.9 −10.3 1.3
652Zr-L1 652 ± 23 1637 ± 77 874 ± 105 0.373 0.262 8.52 −8.7 0.4
Zr-L2 211 ± 11/371 ± 38c 709 ± 13 237 ± 26 0.242 0.361 36.5 −8.7 0.4
Zr-L3 >400d 961 ± 16 596 ± 18 0.412 0.411 23.4 −10.4 0.3
Zr-L4 129 ± 19/266 ± 34c 828 ± 84 165 ± 1 0.282 0.151 42.7 −11.5 0.7
Zr-L5 78 ± 3 1319 ± 247 86 ± 13 0.392 0.397 8.0 −10.8 1.0
Zr-L6 115 ± 12/255 ± 14c 12 742 ± 3319 137 ± 25 0.488 0.445 −5.8 −8.8 6.3
aMeasured by SEM. bMeasured by DLS. cTwo diﬀerent populations of particle sizes were present. dPopulation too heterogeneous to determine
particle size.
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because of its hydrophilic character, which makes it unable to
cross the cell membrane and thus requires a DDS to be
transported through it.17,42 We have previously studied the
release of calcein from all the MOFs in PBS, conﬁrming that
leakage of the dye is similar for all of them.17 Figure S1 presents
the powder X-ray diﬀraction (PXRD) patterns for the
synthesized MOFs compared with the patterns predicted
from single crystal structures. Figure S2 shows the scanning
electron microscopy (SEM) images of the xZr-L1 MOFs and of
the functionalized derivatives. Table 1 shows the particle sizes,
ranging from 50−652 nm for Zr-L1 and from 78 to >400 nm
for Zr-L2−Zr-L6 (obtained from the SEM images). Since the
physicochemical properties of MOFs, and of nanoparticles in
general, are aﬀected by the media in which they are present, we
determined their colloidal properties: hydrodynamic size in
PBS and growth media, z-potential in water and growth media,
all at pH 7.4. The zeta potential is the eﬀective surface potential
at the hydrodynamic “shear surface” close to the solid−liquid
interface. It determines the electrostatic repulsion between
particles, or between particles and a surface such as a cell
membrane, that acts to promote or prevent particle attraction
and adhesion. We expect that the diﬀerent surface function-
alities with diﬀering charges will aﬀect the surface properties
and hence the colloidal and uptake properties of the MOF
particles. Table 1 shows the hydrodynamic diameter of all the
analyzed MOFs in PBS and growth media. The degree of
aggregation was much more pronounced in PBS than in growth
media, for example, the hydrodynamic diameter of Zr-L6 is two
orders of magnitude less in growth media compared to PBS.
The hydrodynamic diameter in growth media indicate
aggregation is only signiﬁcant for the smaller particle size Zr-
L1 samples. We also observed a decrease in the polydispersity
index, which ranged from 16% for 50Zr-L1 to 50% for 92Zr-L1.
MOFs are susceptible to aggregation in aqueous solvents due to
their varying hydrophobicities.37 However, the formation of a
“protein corona”43 on the external surface of the MOF particles,
resulting from the adsorption of diﬀerent kinds of proteins from
the growth media, might be the reason for their lower
susceptibility to aggregation compared to PBS and also the
negative zeta potentials measured in media compared to water.
The amounts of calcein loaded in all the MOFs, with values
ranging between 0.3 and 6.3 wt % for Zr-L3 and Zr-L6,
respectively, are presented in Table 1. For Zr-L1, the amount of
loaded calcein decreases with increasing particle size. Since
smaller particles have higher external surface areas compared
with larger particles, this suggests that calcein mostly adsorbs
on the external surface or to potential superﬁcial defects or
roughness. In the case of the functionalized MOFs (i.e., Zr-L2−
L4), the loading values are generally lower compared to the
nonfunctionalized xZr-L1 particles, even for particles similar in
size such as 260Zr-L1 (260 nm; 1.3 wt %) and Zr-L4 (266 nm;
0.7 wt %). In the case of Zr-L6, that is, the MOF with the
longest linker and therefore largest cavities, the amount
increased to ∼6 wt %, suggesting some additional adsorption
in the internal porosity as well as the outer surface. In all cases,
loading values were suﬃciently high to detect the MOFs
through ﬂow cytometry and confocal microscopy.
Uptake Eﬃciency of Zr-L1 with Diﬀerent Particle
Sizes. The MOFs with diﬀerent linker functionalities included
in our study also present diﬀerent particle sizes. To be able to
discriminate between the role of surface chemistry and particle
size on the endocytosis pathways and uptake eﬃciencies, we
split the analysis to study both eﬀects separately. As a reference
for the surface chemistry analysis, we ﬁrst investigated the eﬀect
of the particle size on the uptake of Zr-L1 using a broad range
of sizes. Figure 1 shows the normalized intracellular
ﬂuorescence, measured by ﬂow cytometry, of HeLa cells
incubated for 1.5 h with xZr-L1 with diﬀerent particles sizes.
We chose the mass ratio of the diﬀerent MOFs in such a way as
to keep the amount of calcein constant and used an equal
amount of free calcein as a control. 50Zr-L1 presented the
highest intracellular ﬂuorescence, and therefore, we normalized
all the values against it. Although calcein is considered an
impermeable dye, a low calcein uptake was observed, 17% in
comparison with 50Zr-L1 uptake. We have seen this eﬀect for
calcein previously, and it has also been observed for other
impermeable dyes, which are internalized by endocytosis.16,18,44
In general, there seems to be a trend of uptake eﬃciency
decreasing with increasing particle size. In the case of 652Zr-L1,
the amount of calcein entering the cell is not signiﬁcantly
diﬀerent from free calcein, showing that very little MOF is
entering the cell, likely due to its large size.
In ﬂow cytometry, cells or particles passing through the laser
beam scatter light, which is detected as forward scatter (FS)
and side scatter (SS). FS correlates with cell size and SS is
proportional to the granularity of the cells. In this manner,
healthy cell populations can often be identiﬁed based on size
and granularity alone. The fact that 652Zr-L1 is not entering the
cells is conﬁrmed by the change in the SS versus FS plot when
cells are incubated with 652Zr-L1 (Figure 2); HeLa cells with
Scheme 1. Organic Linkers Used To Synthesize Zr-Based
MOFs
Figure 1. Normalized intracellular ﬂuorescence of HeLa cells
incubated with Zr-L1 of diﬀerent particle sizes. We used diﬀerent
concentrations of each MOF to keep the amount of calcein constant.
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normal size and granularity mostly fall within the gate seen in
Figure 2a (93.3%). When cells are incubated with 652Zr-L1,
there is a signiﬁcant increase in side scatter (Figure 2b),
indicating an increase in granularity due to MOFs adhered to
the outside of cells. Only 22.7% of cells remain in the gate
where healthy HeLa cells should be, and within this population
there is very little detectable ﬂuorescence, indicating that very
little MOF is taken up by cells. In contrast, cells incubated with
260Zr-L1 have normal side scatter (Figure 2c), with 91.1% of
cells falling within the gate, indicating that the granularity of the
cells is normal and hence that there is no MOF stuck on the
outer cellular membrane.
Inﬂuence of Diﬀerent Endocytosis Inhibitors on the
Cellular Uptake of Zr-L1.We studied the endocytic pathways
(clathrin, caveolae, and clathrin- and caveolae-independent
endocytosis) for the internalization of Zr-L1 by HeLa cells
using diﬀerent pharmacological inhibitors. First, we used
sucrose and chlorpromazine to independently inhibit clathrin-
mediated endocytosis. Sucrose plays a role in the scattering of
clathrin matrices on the cell membrane, whereas chlorproma-
zine inhibits clathrin-coated pit formation by reversibly
translocating clathrin and its adaptor proteins from the plasma
membrane to intracellular vesicles.26,45 Second, we used
nystatin, a polyene antibiotic that sequestrates cholesterol
molecules from the cell membrane, to inhibit caveolae-mediated
endocytosis.45 Finally, we used rottlerin to hinder macro-
pinocytosis by inhibiting kinase proteins.46 To evaluate the
eﬃcacy of these inhibitors we used speciﬁc tracers of the
endocytic pathways: transferrin, ceramide and dextran for
clathrin- and caveolae-mediated endocytosis, and macropinocy-
tosis, in turn.26,47 Since the inhibition of one particular
endocytic pathway may trigger compensatory uptake mecha-
nisms with time,45 we assessed the internalization of the
particles after a short exposure time to the endocytosis
inhibitors (ca. 2 h).
Figure 3 shows HeLa cells’ internal ﬂuorescence after
incubation with xZr-L1 in the presence of the diﬀerent
endocytic inhibitors; Table S1 shows the values for each
sample. To determine if the diﬀerences were statistically
signiﬁcant, we compared every value to the control at 37 °C
using one-way analysis of variance (ANOVA) followed by
Dunnett’s test to adjust for multiple comparisons (Table S2).
Cellular uptake of the MOFs was signiﬁcantly reduced by
∼85% when cells were incubated at 4 °C. At this temperature,
the metabolic activity of a cell is signiﬁcantly reduced,45
conﬁrming that the particles were taken up by energy-
dependent endocytosis and not by passive diﬀusion. For 50Zr-
L1, particle uptake decreased signiﬁcantly to 29% when cells
were treated with hypertonic sucrose. Despite the fact that
sucrose is considered an inhibitor of clathrin-mediated
endocytosis,48,49 there is evidence suggesting that it has some
eﬀect on non-clathrin-mediated endocytosis pathways.50 For
this reason, we used chlorpromazine to reconﬁrm the sucrose
result as there is no evidence that it aﬀects caveolae-mediated
endocytosis or other endocytic pathways.45 For chlorproma-
zine, the uptake decreased only moderately to 86%, although
this was not statistically diﬀerent from the control at 37 °C.
The fact that sucrose aﬀects uptake while chlorpromazine does
not suggests that the main uptake routes of 50Zr-L1 do not
involve clathrin-mediated pathways, and that, in this case,
sucrose is inhibiting non-clathrin-mediated endocytosis path-
ways. Similarly, 50Zr-L1 particle uptake moderately decreased to
94 and 83% when cells were treated with nystatin and rottlerin
Figure 2. Side scatter versus forward scatter plot obtained from ﬂuorescence-activated cell sorting (FACS) of (a) HeLa cells, (b) HeLa cells
incubated with 652Zr-L1, and (c) HeLa cells incubated with 260Zr-L1. Solid red line shows the gate around morphologically normal HeLa cells. The
numbers indicate the percentage of cells within that gate.
Figure 3. Eﬀects of pharmacological endocytosis inhibitors on the
uptake of Zr-L1 with diﬀerent particle sizes, measured by ﬂow
cytometry.
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respectively, again, this was not statistically diﬀerent from the
control at 37 °C. This indicates that the main routes of entry of
50Zr-L1 do not involve clathrin- or caveolae-mediated
endocytosis, or macropinocytosis, but clathrin- and caveolae-
independent endocytosis. For 75Zr-L1 and 92Zr-L1, similar
levels of inhibition by chlorpromazine, nystatin, and rottlerin
were observed, decreasing to ∼45, 84, and 78%, respectively,
for both MOFs. However, the signals for these MOFs when
treated with nystatin and rottlerin were not statistically
signiﬁcantly diﬀerent from the control, indicating that they
mainly enter the cell through clathrin-mediated endocytosis. In
the case of 75Zr-L1, the decrease when treated with nystatin and
rottlerin was slightly greater than that observed for 92Zr-L1 and
showed some statistical signiﬁcance, suggesting perhaps some
uptake by caveolae-mediated endocytosis and macropinocytosis.
For 260Zr-L1, the decrease in ﬂuorescence intensity when
treated with nystatin and rottlerin was the same as 75Zr-L1
(down to 78% and 75% respectively) and was statistically
signiﬁcant. However, an even larger decrease in intensity was
observed for chlorpromazine, suggesting that, for 260Zr-L1,
clathrin-mediated endocytosis again dominates.
The decrease in internal ﬂuorescence when using chlorpro-
mazine is diﬀerent than what we obtained in our previous work
for similar particle size.18 The discrepancy comes from the
diﬀerent synthesis protocol and modulators used: HCl and
benzoic acid versus acetic acid here. The colloidal stability and
properties of UiO-66 are highly dependent on the modulator
conditions utilized in the synthesis. This is due to the fact that
modulators at higher concentrations and lower pKa lead to the
formation of more defects in the crystals, which in turn alter the
surface chemistry of UiO-66 and enhance its colloidal stability.
Table 2 summarizes the statistical signiﬁcance for compar-
ison between the intracellular ﬂuorescence of the diﬀerent
MOFs treated with a given inhibitor. The results show that
there is no statistically signiﬁcant diﬀerence between the
normalized intracellular ﬂuorescence of the Zr-L1 MOFs of
diﬀerent sizes when treated with nystatin (i.e., for caveolae) and
rottlerin (i.e., macropinocytosis). This is despite the fact that
Table S2 shows that decreases in ﬂuorescence for 75Zr-L1and
260Zr-L1 with these inhibitors are statistically signiﬁcant when
compared to the control at 37 °C. In general, it seems that
particle size of the materials included in this study does not
greatly aﬀect the uptake pathway. A minor diﬀerence is found
for 75Zr-L1, and more signiﬁcantly for 260Zr-L1, which exhibit
some endocytosis by the caveolin-mediated pathway, and in
doing so avoid degradation in the lysosomes.
Internalization Eﬃciency of Zr-Based MOFs with
Diﬀerent Surface Chemistry. Following the analysis of the
role of particle size on the internalization of the MOF particles,
we continued with the MOFs with diﬀerent surface chemistries.
As mentioned above, the particle size of these MOFs ranged
from 78 to more than 400 nm, for Zr-L5 and Zr-L3,
respectively. Figure 4 presents the normalized internal
ﬂuorescence of HeLa cells after treatment for 1.5 h with the
functionalized MOFs, Zr-L2 to Zr-L6 (0.5 mg/mL), or free
calcein (equivalent to the same amount loaded in each MOF
for normalization purposes). We considered the highest value
as 100%, which corresponded to Zr-L3. Among all the MOFs,
Zr-L3 was internalized more eﬃciently than any of the others,
followed by Zr-L2 then Zr-L4. The less eﬃcient MOFs were
Zr-L5 and Zr-L6. Interestingly, we did not observe the same
trend of decreasing eﬃciencies with increasing particle sizes
that we found with xZr-L1 samples, conﬁrming the importance
of surface chemistry. This is further conﬁrmed by noting that
for xZr-L1 particles the variability in the uptake eﬃciency is low
(with the exception of 650Zr-L1, which is too large to be taken
up), whereas for Zr-L2 to Zr-L6 the variability is much larger.
For the MOFs with functionalized ligands (i.e., −Br, −NO2,
and −NH2, for Zr-L2, Zr-L3, and Zr-L4, respectively), cellular
uptake seems to be inversely related to zeta potential (Table 1).
Zr-L3, which has the highest uptake, has a zeta potential of 23.4
mV, followed by Zr-L2 (36.5 mV) and Zr-L4 (42.7 mV). The
MOFs with extended linkers (i.e., Zr-L5 and Zr-L6) have low
zeta potentials of 8.0 and −5.8 mV, respectively, which might
Table 2. Comparison of Normalized Internal Fluorescence
of HeLa Cells Treated with Each MOF and Diﬀerent
Pharmacological Inhibitorsa
MOF vs MOF sucrose chlorpromazine nystatin
clathrin clathrin caveolae
50Zr-L1 vs 75Zr-L1 ns ∗∗ ns
50Zr-L1 vs 92Zr-L1 ∗∗ ∗∗ ns
50Zr-L1 vs 260Zr-L1 ∗∗ ∗∗∗ ns
75Zr-L1 vs 92Zr-L1 ∗ ns ns
75Zr-L1 vs 260Zr-L1 ∗∗ ∗ ns
92Zr-L1 vs 260Zr-L1 ns ∗ ns
Zr-L2 vs Zr-L3 ns ns ns
Zr-L2 vs Zr-L4 ns ∗∗ ns
Zr-L3 vs Zr-L4 ns ∗∗ ns
Zr-L2 vs Zr-L5 ∗∗ ∗∗∗∗ ∗∗∗
Zr-L2 vs Zr-L6 ∗∗∗ ∗∗∗∗ ∗∗∗∗
Zr-L3 vs Zr-L5 ∗∗ ∗∗∗∗ ∗∗
Zr-L3 vs Zr-L6 ∗∗∗ ∗∗∗∗ ∗∗
Zr-L4 vs Zr-L5 ∗∗ ∗∗∗∗ ∗∗∗
Zr-L4 vs Zr-L6 ∗∗∗ ∗∗∗∗ ∗∗∗
Zr-L5 vs Zr-L6 ns ns ns
aStatistical signiﬁcance, determined by unpaired t test (no signiﬁcance,
ns, P > 0.05, ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001, ∗∗∗∗P ≤ 0.0001).
Rottlerin (macropinocytosis) has not been included because all the
results show no signiﬁcance.
Figure 4. Normalized intracellular ﬂuorescence of HeLa cells
incubated with Zr-L2 to Zr-L6. We used diﬀerent calcein
concentrations as controls for each MOF so that they were equivalent
to the loaded amount in the respective MOF; z-potential values shown
at top of bars, particle size at the bottom.
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explain why they are not signiﬁcantly taken up by the cells.
Indeed, it has been reported that surface charge has a critical
role in cellular uptake and drug delivery systems, where positive
charged nanoparticles show higher uptake eﬃcacy.51 The
reason for this is the higher attraction of cationic NPs could be
related to the negatively charged plasma membrane of cells.52,53
Interestingly, we can see that the zeta potential values for all the
MOFs in media converge to around −10 mV, which is the zeta
potential measured for growth media. This conﬁrms the
“protein corona” formation around the external surface of the
particles.
Inﬂuence of Endocytosis Inhibitors on the Cellular
Uptake of Zr-Based MOFs with Diﬀerent Surface
Chemistry. After the analysis of the endocytosis eﬃciency,
we then moved to study the diﬀerent endocytic pathways.
Figure 5 shows HeLa cells’ internal ﬂuorescence after
incubation with each MOF (0.5 mg/mL) in the presence of
diﬀerent endocytic inhibitors. The uptake of all the MOFs was
highly inhibited at 4 °C, between 74 and 88% lower than the
corresponding control at 37 °C. On the basis of the results, and
as with the endocytosis eﬃciency discussed above, it was
possible to segregate the MOFs into two subgroups regarding
the endocytosis pathways used by cells for their internalization:
(i) MOFs with functional groups, and (ii) MOFs with extended
linkers. On one hand, the uptake of Zr-L2, Zr-L3, and Zr-L4
decreased to values close to 20% after incubation with sucrose
and chlorpromazine (i.e., clathrin-mediated endocytosis inhib-
itors), whereas exposure to nystatin (i.e., caveolae-mediated
endocytosis inhibitors) had a moderate eﬀect of ∼70%, and
rottlerin (i.e., macropinocytosis inhibitor) reduced the uptake to
∼48%. On the other hand, the uptake of Zr-L5 and Zr-L6 was
greatly inhibited when caveolae-mediated endocytosis was
blocked by nystatin, decreasing to ∼42%. Inhibition of
clathrin-mediated endocytosis on these systems only had a
moderate eﬀect, decreasing to ∼65 and 90% for sucrose and
chlorpromazine, respectively. Inhibition with chlorpromazine
showed no statistical signiﬁcance with respect to the controls
for both Zr-L5 and Zr-L6. Rottlerin decreased the uptake of
these two MOFs to ∼67%. As observed above for xZr-L1
samples, in some cases the eﬀect of sucrose on the MOF uptake
was more dramatic than chlorpromazine due to pathways other
than clathrin-mediated routes being blocked.45,50 The literature
oﬀers conﬂicting data about the selection of endocytic pathways
for charged particles, probably because the process is cell-
speciﬁc. However, studies on Hela cells using charged NPs
support clathrin-mediated endocytosis for positively charged
particles, and clathrin-independent for negatively charged
ones.54,55 This may explain why Zr-L6, negatively charged, is
internalized mainly through caveolae-mediated endocytosis.
Table 2 shows the comparison of the normalized internal
ﬂuorescence values for each MOF with the others after
exposure to the inhibitors, allowing the statistical diﬀerences
within these two subgroups and between them to be
determined. First, the only signiﬁcant diﬀerence (P ≤ 0.01)
within the group of functionalized MOFs (Zr-L2, Zr-L3, and
Zr-L4) was between Zr-L4, and Zr-L2 and Zr-L3, when treated
with chlorpromazine. We did not observe any signiﬁcant
diﬀerence between these three MOFs when treated with
nystatin or rottlerin. The same was true in the case of the
subgroup of extended linkers, that is, Zr-L5 and Zr-L6, where
we did not observe any signiﬁcant diﬀerence within them, for
any inhibitor used. Conversely, there were signiﬁcant diﬀer-
ences when we compared the values for the functionalized
MOFs, Zr-L2, Zr-L3, and Zr-L4, with the values for Zr-L5 and
Zr-L6, for sucrose, chlorpromazine, and nystatin. This result
conﬁrms that the cellular uptake behavior is diﬀerent between
the two subgroups (MOFs with functionalities vs MOFs with
extended linkers). The size of the particles could play a minor
role in inter- and intragroup diﬀerences, as we have seen that
the cell uptake behavior is less aﬀected by a change in the size
of Zr-L1 in comparison to the surface chemistry of the MOFs,
which is greatly aﬀecting these processes. However, more
importantly, the surface chemistry of the particles is aﬀecting
these processes. The two subgroups of MOFs can also be
segregated with respect to zeta potential. The MOFs with
functionalities (Zr-L2 to Zr-L4) have zeta potentials in the
range of 23.4−42.7 mV, while the MOFs with extended linkers
(Zr-L5 and Zr-L6) have low zeta potentials of 8.0 and −5.8
mV, respectively. MOFs with functional groups and thus higher
zeta potentials undergo preferably clathrin-mediated endocy-
tosis, and the MOFs with extended linkers and thus low surface
charge are internalized mostly through caveolae-mediated
endocytosis. xZr-L1 particles do not have functional groups,
but their surface charge is slightly greater than Zr-L5 and Zr-L6,
which might be due to the higher surface density of clusters on
their surface compared to the MOFs with extended linkers. The
high propensity of UiO-66 to have defects might also play a
role in increasing the surface charge.56 This can explain why
xZr-L1 particles, with a surface charge between that of the
functionalized MOFs and that of the extended linker MOFs, go
through clathrin-mediated endocytosis in addition to caveolae-
mediated endocytosis, whereas Zr-L5 and Zr-L6 only go
through caveolae-mediated endocytosis. It is noteworthy that all
MOFs are also internalized by macropinocytosis as it is a
nonselective process carried out by cells.
Inﬂuence of the Uptake Pathway on the Final Fate of
Zr-Based Family MOFs, Colocalization Studies. Depend-
ing on the type of endocytosis, the internalized carrier and
loaded molecules are transported through diﬀerent metabolic
pathways. They are then processed, contained in vesicles, to
their ﬁnal intracellular destination.57 As explained above,
particles that undergo caveolae-mediated endocytosis can
potentially bypass lysosomal acidic degradation. Studies on
viruses and bacteria provide strong evidence that they are
internalized through this pathway, and they are able to avoid
digestion in the lysosomes.58 On the basis of this, one can
Figure 5. Eﬀects of pharmacological endocytosis inhibitors on the
uptake of Zr-based family MOFs, measured by ﬂow cytometry.
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expect that MOFs would have a higher chance of avoiding the
lysosome and, thus, delivering their cargo in other intracellular
locations if they are internalized by caveolae-mediated
endocytosis, for example, Zr-L5 and Zr-L6. We consequently
investigated the intracellular fate of the MOFs after the
endocytosis process, in particular, by examining whether the
MOFs were found in lysosomes for further acidic degradation.
For this purpose, we used confocal ﬂuorescence microscopy to
determine if the particles were in the same intracellular location
as a lysosome marker, LysoTracker-Deep Red. We also
measured the Manders’ overlap coeﬃcient (MOC), which
varies from 0 to 1 for nonoverlapping and complete
colocalization, respectively.59,60 Figure 6a shows the images
obtained from confocal microscopy of HeLa cells incubated
with each MOF and LysoTracker-Deep Red. At 2 h, we
observed a high degree of colocalization between Zr-L2, Zr-L3,
Zr-L4, and LysoTracker-Deep red, which is illustrated by the
yellow color in the merged images. In the case of Zr-L5 and Zr-
L6, we found only a moderate correlation between the MOFs
and LysoTracker-Deep Red, which was conﬁrmed by
quantiﬁcation analysis using MOC (Figure 6b). It was again
possible to identify the two subgroups of MOFs: (i) Zr-L2, Zr-
L3, and Zr-L4; and (ii) Zr-L5 and Zr-L6. Within the ﬁrst
subgroup, all the MOFs behave in the same way (average MOC
ca. 0.8, with no statistically signiﬁcant diﬀerence between
them); the same occurs with the second subgroup (average
MOC ca. 0.4, with no statistically signiﬁcant diﬀerence). By
comparing the two subgroups, the colocalization degree of Zr-
L5 and Zr-L6 was on average ∼50% lower than that of Zr-L2 to
Zr-L4 (Table S3 shows the statistical analysis of the MOC for
each MOF compared with the others). This result indicates that
Zr-L2, Zr-L3, and Zr-L4 are mostly localized in lysosomes for
further acidic degradation, whereas a signiﬁcant quantity of Zr-
L5 and Zr-L6 may be able to successfully avoid it and
potentially release the cargo in the cytosol or other organelles.
On the basis of all these results, we can see correlations of
both the particle size and linker functionalities (and thus
surface chemistry) with the uptake eﬃciency and ﬁnal fate of
the MOFs inside cells. Without a doubt, overall uptake
eﬃciency is an important feature, but MOFs entrapped in
endosomes or lysosomes do not contribute to the ﬁnal aim of
delivering drugs in the cytosol and so this may lead to a
reduced therapeutic eﬀect. For instance, this is the case of Zr-
L3, which is the most successful MOF in terms of cellular
uptake; however, after the endocytosis process, it was found in
the lysosomes for further degradation. In contrast, Zr-L5 and
Zr-L6 were the least eﬃcient in terms of cellular uptake;
however, they could avoid the lysosomes and potentially deliver
their cargo in the cytosol with an improved therapeutic result.
We have previously investigated the cytotoxicity of Zr-L1 to
Zr-L6 loaded with α-cyano-4-hydroxycinnamic acid (α-CHC)
and found α-CHC@Zr-L6 to be more toxic than α-CHC@Zr-
L1.17 With our newly acquired knowledge of the endocytosis
pathways, we are able to rationalize these results (reproduced in
Figure 7) in more depth. We did not ﬁnd any signiﬁcant
diﬀerence in viability for cells treated with empty and α-CHC-
loaded Zr-L1 to Zr-L5, with viability remaining above 80% for
both conditions at any given concentration of MOF (data for
Zr-L1, Zr-L3, and Zr-L6 are shown in Figure 7). Empty Zr-L6
is also noncytotoxic at the concentrations used. α-CHC@Zr-
L6, however, decreases the viability down to 59 ± 5% at a MOF
concentration of 1 mg mL−1. This once again conﬁrms that
even though Zr-L3 is more eﬃcient than Zr-L6 at delivering
cargo into the cell, it is less therapeutically eﬀective than the
latter since most of the cargo ends up being degraded in the
lysosomes. A comparison of Zr-L1 and Zr-L6 also conﬁrms that
it is not necessarily the amount of drug loaded in the MOF that
Figure 6. (a) Confocal microscopy images of HeLa cells incubated
with Zr-based MOFs loaded with calcein (green ﬂuorescence, i.e.,
calcein), and LysoTracker-Deep red (red ﬂuorescence), for 2 h. (b)
Manders’ overlapping coeﬃcient for all the MOF samples and the
lysosome marker. Error bars represent the standard error of at least 10
independent images.
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determines its eﬃcacy, given that Zr-L1, which has a higher
loading than Zr-L6, is still less eﬀective at killing cells.
■ CONCLUSIONS
We have synthesized a range of Zr-based MOFs of diﬀerent
sizes and with diﬀerent surface chemistries and showed, using
the ﬂuorescent molecule calcein, that they enter cells through
diﬀerent endocytic pathways. We have demonstrated that
control of surface chemistry, in this case through linker
functionalization, is critical to tune the pathways in which cells
take up particles, whereas particle size does not exert a great
inﬂuence here. We showed that Zr-L1 (nonfunctionalized) and
Zr-L3 (−NO2 functionalized), for example, are taken up mostly
by clathrin-mediated endocytosis and end up being degraded in
the lysosomes, voiding their therapeutic eﬀect. On the other
hand, Zr-L5 and Zr-L6, although they are much less eﬃcient at
entering cells, are taken up through the caveolae-mediated
route, allowing them to avoid lysosomal degradation, and to
release their cargo in the desired intracellular location. Finally,
we conﬁrmed these ﬁndings by evaluating the therapeutic eﬀect
of each Zr-based MOF loaded with α-CHC, with the ﬁndings
showing an enhanced eﬀect of the drug when loaded within Zr-
L6. All these results demonstrate the importance of designing a
suitable and eﬃcient drug delivery vector and the chemical
ﬂexibility that MOFs oﬀer for this aim. For future experiments,
the shape of particles may be included as a new variable, as it is
another intrinsic characteristic of particles that aﬀects the
cellular uptake.61,62
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